Live from the NIH registry
Studies recruiting near Fresno right now
Top 25 of 170 recruiting studies, sorted by proximity — each links to its official registry page
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Chronic Migraine
Phase 3
Interventional 420 participants sought
Neuro Pain Research Center /ID# 271048 — Fresno, California (2.7 mi)
· Sponsor: AbbVie
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma
Phase 3
Interventional 1,273 participants sought
Fresno Cancer Center — Fresno, California (2.7 mi)
· Sponsor: SWOG Cancer Research Network
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy (SMA)
N/A
Observational 700 participants sought
Valley Children's Healthcare — Madera, California (19.2 mi)
· Sponsor: Novartis Pharmaceuticals
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Multiple Myeloma
Phase 3
Interventional 893 participants sought
University of California San Francisco — Fresno, California (2.7 mi)
· Sponsor: Pfizer
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Phase 2
Interventional 48 participants sought
Valley Children's Hospital — Madera, California (19.2 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
Kaiser Permanente Fresno Orchard Plaza — Fresno, California (2.7 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Phase 2
Interventional 156 participants sought
Kaiser Permanente Fresno Orchard Plaza — Fresno, California (2.7 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
Urinary Tract Infections
Phase 2
Interventional 318 participants sought
Research Site 138 — Fresno, California (2.7 mi)
· Sponsor: Locus Biosciences
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
Muscular Atrophy, Spinal
Phase 4
Interventional 28 participants sought
Valley Children's Hospital — Madera, California (19.2 mi)
· Sponsor: Hoffmann-La Roche
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Pulmonary Hypertension, Interstitial Lung Disease
N/A
Observational 80 participants sought
The Medical Research Group, Inc. — Fresno, California (2.7 mi)
· Sponsor: Liquidia Technologies, Inc.
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Phase 2
Interventional 130 participants sought
Community Cancer Institute (CCI) — Clovis, California (5.8 mi)
· Sponsor: Hoffmann-La Roche
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Phase 3
Interventional 228 participants sought
Kaiser Permanente Fresno Orchard Plaza — Fresno, California (2.7 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Phase 3
Interventional 382 participants sought
Fresno Cancer Center — Fresno, California (2.7 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
High Grade Osteosarcoma, Localized Osteosarcoma
Phase 2, Phase 3
Interventional 1,122 participants sought
Valley Children's Hospital — Madera, California (19.2 mi)
· Sponsor: National Cancer Institute (NCI)
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis, Multiple Sclerosis
N/A
Observational 2,000 participants sought
TG Therapeutics Investigational Trial Site — Fresno, California (2.7 mi)
· Sponsor: TG Therapeutics, Inc.
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Parkinson Disease, Parkinson
Phase 2
Interventional 150 participants sought
Neuro-Pain Medical Center — Fresno, California (2.7 mi)
· Sponsor: Neuron23 Inc.
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Multiple conditions
Phase 2
Interventional 314 participants sought
Community Cancer Institute — Clovis, California (5.8 mi)
· Sponsor: National Cancer Institute (NCI)
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
End Stage Kidney Disease
Phase 2, Phase 3
Interventional 3,110 participants sought
The Medical Research Group, Inc. — Fresno, California (2.7 mi)
· Sponsor: CSL Behring
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Phase 3
Interventional 1,500 participants sought
Fresno Cancer Center — Fresno, California (2.7 mi)
· Sponsor: NRG Oncology
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
Prostate Adenocarcinoma
Phase 1
Interventional 45 participants sought
Urology Associates of Central California — Fresno, California (2.7 mi)
· Sponsor: Alessa Therapeutics Inc.
IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers
Wound Heal, Ulcer
N/A
Interventional 235 participants sought
Limb Preservation Platform — Fresno, California (2.7 mi)
· Sponsor: ConvaTec Inc.
International Rare Histiocytic Disorders Registry (IRHDR)
Rare Histiocytic Disorders (RHDs), Erdheim-Chester Disease (ECD)
N/A
Observational 400 participants sought
Valley Children's Hospital — Madera, California (19.2 mi)
· Sponsor: The Hospital for Sick Children
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Childhood Medulloblastoma
Phase 3
Interventional 225 participants sought
Valley Children's Hospital — Madera, California (19.2 mi)
· Sponsor: Children's Oncology Group
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Phase 3
Interventional 170 participants sought
UCSF FRESNO/Community Cancer Institute /ID# 270874 — Clovis, California (5.8 mi)
· Sponsor: AbbVie
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathic Pain
Phase 3
Interventional 1,100 participants sought
Neuro-Pain Medical Center — Fresno, California (2.7 mi)
· Sponsor: Vertex Pharmaceuticals Incorporated